.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,388,941

« Back to Dashboard

Claims for Patent: 8,388,941

Title:Self preserved aqueous pharmaceutical compositions
Abstract: The use of a borate/polyol and zinc system to enhance the antimicrobial activity of multi-dose pharmaceutical compositions is described. The compositions do not require a conventional anti-microbial preservative and therefore are referred to as being `self-preserved`. The compositions possess sufficient antimicrobial activity to satisfy the preservative efficacy requirements of the USP for aqueous ophthalmic compositions.
Inventor(s): Chowhan; Masood A. (Arlington, TX), Keith; David J. (Washington, MO)
Assignee: Alcon Research, Ltd. (Fort Worth, TX)
Application Number:12/441,995
Patent Claims: 1. A multi-dose, self-preserved ophthalmic composition, said composition comprising: a therapeutically effective amount of an ophthalmic therapeutic agent selected from the group consisting of beta-blockers, carbonic anhydrase inhibitors, prostaglandin analogs, neuroprotectants, anti-angiogenesis agents, quinolones, anti-inflammatory agents, growth factors, immunosuppressant agents and anti-allergic agents; and a preservative system consisting essentially of: i. borate at a concentration in the composition of 0.3 to 1.5 w/v % wherein the borate comprises one or more borates; ii. polyol at a concentration in the composition of 0.6 to 2.0 w/v % wherein the polyol comprises sorbitol and propylene glycol; and iii. zinc ions, wherein the zinc ions are provided by zinc chloride at a concentration in the composition of 0.0005 to 0.005 w/v %; wherein the preservative system has sufficient antimicrobial activity to allow the composition to satisfy USP 26 preservative efficacy requirements.

2. A composition as in claim 1 wherein the therapeutic agent is a prostaglandin analog.

3. A composition as in claim 1 wherein the therapeutic agent is travoprost.

4. A method of enhancing the antimicrobial activity of an aqueous ophthalmic pharmaceutical composition, which comprises including a preservative system in the composition, the preservative system consisting essentially of: i. borate at a concentration in the composition of 0.3 to 1.5 w/v % wherein the borate comprises one or more borates; ii. polyol at a concentration in the composition of 0.6 to 2.0 w/v % wherein the polyol comprises sorbitol and propylene glycol; and iii. zinc ions, wherein the zinc ions are provided by zinc chloride at a concentration in the composition of 0.0005 to 0.005 w/v %; wherein: i. the preservative system has sufficient antimicrobial activity to allow the composition to satisfy USP 26 preservative efficacy requirements; and ii. the composition includes a therapeutically effective amount of an ophthalmic therapeutic agent selected from the group consisting of beta-blockers, carbonic anhydrase inhibitors, prostaglandin analogs, neuroprotectants, anti-angiogenesis agents, quinolones, anti-inflammatory agents, growth factors, immunosuppressant agents and anti-allergic agents.

5. A method as in claim 4 wherein the therapeutic agent is a prostaglandin analog.

6. A method as in claim 4 wherein the therapeutic agent is travoprost.

7. A composition as in claim 1 wherein the concentration of borate in the composition is 0.5-1.2 w/v %.

8. A composition as in claim 3 wherein the concentration of borate in the composition is 0.5-1.2 w/v %.

9. A method as in claim 4 wherein the concentration of borate in the composition is 0.5-1.2 w/v %.

10. A method as in claim 6 wherein the concentration of borate in the composition is 0.5-1.2 w/v %.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc